Evidence map›Paper›PMID 32971147›Full record

ReviewBiochimie2020

The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2.

Shibi Muralidar, Senthil Visaga Ambi, Saravanan Sekaran, Uma Maheswari Krishnan

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biochimie, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 167 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
167citing papers in PubMed, 8 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

167 citing papers in PubMed, 8 syntheses or guidelines pooled it, 350 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Review

107 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Shibi MuralidarSchool of Chemical and Biotechnology, SASTRA Deemed-to-be-University, Thanjavur, 613401, Tamil Nadu, India.
Senthil Visaga AmbiSchool of Chemical and Biotechnology, SASTRA Deemed-to-be-University, Thanjavur, 613401, Tamil Nadu, India. Electronic address: senthilvisagaambi@scbt.sastra.edu.
Saravanan SekaranSchool of Chemical and Biotechnology, SASTRA Deemed-to-be-University, Thanjavur, 613401, Tamil Nadu, India; Centre for Nanotechnology & Advanced Biomaterials (CeNTAB), School of Chemical and Biotechnology, SASTRA Deemed-to-be-University, Thanjavur, 613401, Tamil Nadu, India.
Uma Maheswari KrishnanSchool of Chemical and Biotechnology, SASTRA Deemed-to-be-University, Thanjavur, 613401, Tamil Nadu, India; Centre for Nanotechnology & Advanced Biomaterials (CeNTAB), School of Chemical and Biotechnology, SASTRA Deemed-to-be-University, Thanjavur, 613401, Tamil Nadu, India; School of Arts, Science & Technology (SASH), SASTRA Deemed-to-be-University, Thanjavur, 613401, Tamil Nadu, India.
SASTRA University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An acute respiratory disease caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that surfaced in China in late 2019, continues to spread rapidly across the globe causing serious concerns. The coronavirus disease 2019 (COVID-19) is declared as a public health emergency worldwide by the World Health Organization (WHO). Increasing evidences have demonstrated human-to-human transmission that primarily affects the upper respiratory tract followed by lower respiratory tract damage leading to severe pneumonia. Based on the current status, the elderly population and people with prior co-morbidities are highly susceptible to serious health effects including cytokine up-regulation and acute respiratory distress syndrome (ARDS). Currently, COVID-19 research is still in the preliminary stage necessitating rigorous studies. There is no specific drug or vaccine targeting SARS-CoV-2 currently and only symptomatic treatment is being administered, but several antivirals are under active investigation. In this review, we have summarized the epidemiology, entry mechanism, immune response, and therapeutic implications, possible drug targets, their ongoing clinical trials, and put forward vital questions to offer new directions to the COVID-19 research.

Indexed as

PandemicsCOVID-19COVID-19 Drug TreatmentHumansMolecular Targeted TherapySARS-CoV-2Clinical trialsImmune responseMERS-CoVSARS-CoVSARS-CoV-2

Identifiers

PMID32971147
PMCPMC7505773
OpenAlexW3087600780

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.